Revance Therapeutics Inc

Latest Results (07.08.2024):

Revenue and Sales

Revance Therapeutics Inc. reported that for the first quarter of 2024, the total net product revenue, which includes sales of DAXXIFY and the RHA Collection, is expected to be at least $280 million. This projection underscores the company's strong market presence and the successful uptake of its products.

Operating Expenses

For the first quarter of 2024, Revance Therapeutics Inc. anticipates GAAP operating expenses from continuing operations to be between $460 million to $490 million. Non-GAAP operating expenses from continuing operations are expected to range between $290 million to $310 million, reflecting the company's strategic investments in growth and development.

SG&A Expenses

Revance Therapeutics Inc. projects non-GAAP SG&A expenses from continuing operations to be between $240 million to $255 million for the first quarter of 2024. This forecast indicates the company's commitment to managing its selling, general, and administrative costs effectively while expanding its market reach.

Financial Position

As of March 31, 2024, Revance Therapeutics Inc. reported having cash, cash equivalents, and short-term investments totaling $277.1 million. This strong cash position, combined with anticipated revenues and expenditures, positions the company to achieve cash flow break-even and positive Adjusted EBITDA by 2025.

Stock Offering

In March 2024, Revance Therapeutics Inc. successfully completed an offering of common stock, generating gross proceeds of $100.0 million. This capital infusion has further bolstered the company's financial standing, providing additional balance sheet optionality to support its strategic initiatives.